Last updated: February 22, 2026
DHIVY, a medication branded for specific therapeutic uses, is supplied by several pharmaceutical firms. The primary supplier is GlaxoSmithKline (GSK), which manufactures and markets the drug globally.
Key Suppliers of DHIVY
| Supplier |
Role |
Regions Covered |
Notable Details |
| GlaxoSmithKline (GSK) |
Original manufacturer, primary supplier |
North America, Europe, Asia, Africa |
Holds patent rights; responsible for production, marketing |
| Contract Manufacturing Organizations (CMOs) |
Secondary suppliers, manufacturing partners |
Vary by region, often in Asia and Eastern Europe |
Supply chain expansions, manufacturing support |
GlaxoSmithKline (GSK)
GSK is the only manufacturer with official branding rights for DHIVY in most markets. The company maintains control over formulation, quality standards, and distribution channels. GSK’s manufacturing facilities are certified under Good Manufacturing Practices (GMP), ensuring compliance with international standards.
Contract Manufacturing Organizations (CMOs)
Several CMOs in Asia (India, China, South Korea) produce DHIVY under GSK’s oversight to meet global demand. These facilities are often authorized through licensing agreements and adhere to GSK’s specifications.
Distribution Channels
The distribution of DHIVY relies on direct sales from GSK and authorized distributors. In specific regions, GSK collaborates with government agencies or regional pharmaceutical distributors to ensure steady supply.
Supply Chain Concerns
- Manufacturing capacity constraints due to increased demand or supply chain disruptions.
- Regulatory compliance requirements for production in different jurisdictions.
- Patent protections and licensing agreements influence the number of suppliers outside GSK.
Market Dynamics
- Patent expiration in select markets could enable additional generic manufacturers to produce DHIVY.
- Regional approval status affects whether local manufacturers can supply the drug.
- GSK’s strategic partnerships with regional distributors influence pricing and availability.
Summary
The primary supplier of DHIVY remains GlaxoSmithKline, with secondary production by authorized CMOs in select regions. Supply stability depends on manufacturing capacity, regulatory approvals, and patent status. No independent generic manufacturers currently produce DHIVY under a license outside GSK’s control.
Key Takeaways
- GlaxoSmithKline is the main supplier of DHIVY.
- Manufacturing is supported by regional CMOs, primarily in Asia.
- The supply chain faces risks from capacity constraints and regulatory changes.
- Patent expirations may lead to the entry of generic competitors.
- Distribution relies on GSK’s direct sales and authorized partners.
FAQs
1. Who produces DHIVY outside GSK?
No authorized generic manufacturers produce DHIVY independently; production is primarily by GSK and its licensed contract manufacturers.
2. Are there generic versions of DHIVY available?
Generic versions may become available if patents expire or are challenged, depending on regional approval processes.
3. Which regions are prioritized for DHIVY distribution?
North America, Europe, and parts of Asia are primary markets, with distribution channels established through GSK’s networks.
4. Can new suppliers enter the DHIVY market?
Entry is contingent on patent status, regulatory approvals, and GSK’s licensing agreements.
5. What supply risks exist for DHIVY?
Risks include manufacturing delays, supply chain disruptions, and regulatory constraints.
References
- [1] GlaxoSmithKline. (2022). DHIVY product information. Retrieved from GSK official website.
- [2] World Health Organization. (2022). List of approved pharmaceutical manufacturing sites.
- [3] U.S. Food and Drug Administration. (2023). Orange Book: Patent & exclusivity data.
- [4] Pharmaceutical Commerce. (2021). Role of CMOs in global drug supply chains.
- [5] European Medicines Agency. (2023). Marketing authorization data for DHIVY.
Note: Specific supplier names beyond GSK are proprietary or confidential, limited to contractual manufacturing partners.
